跳到主要內容

研究成果

2025年論文發表

  1. Chang KC, Chang MH*. Current status and unmet needs of pediatric HCV infection in Taiwan. J Formos Med Assoc. 2025 Nov 3:S0929-6646(25)00585-6.
  2.  Hong CM, Su TH, Hsu SJ, Tseng TC, Liu CH, Yang HC, Kao JH, Chen PJ, Cheng PN, Hung CH, Peng CY, Chen CH, Lin CY, Kuo HT, Lin HC, Huang YH, Chen CY, Lin CL, Tsai PC, Zeng YS, Dai CY, Chuang WL, Huang JF, Huang CF, Yeh ML, Yu ML, Liu CJ. Addition of neutrophil-to-lymphocyte ratio to Pre-DAA FIB-4 does not increase prediction value for <i>de novo</i> liver complications in hepatitis C. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION,124(12),1149-1156
  3. Chang HH, Lee YH, Huang KC, Chan DC, Lin YC, Sheng WH, Lee LT, Huang LM. COVID-19 vaccination: 2023 Taiwan Association of Gerontology and Geriatrics (TAGG) consensus statements. J Formos Med Assoc. 2025 Apr; 124(4): 304-310. 
  4. Chang KC, Chang MH, Chen HL, Wu JF, Su WJ, Yang YJ, Lu FT, Chang YC, Ni YH. Secular trend in hepatitis A infection and effect of hepatitis a vaccination: A nationwide surveillance in Taiwan, 2019-2020. J Formos Med Assoc. 2025 Dec 8:S0929-6646(25)00646-1.
  5. Chang KC, Su TH, Kao JH. Reply on "Tenofovir is Associated With a Better Prognosis Than Entecavir for Hepatitis B Virus-related Hepatocellular Carcinoma". Clin Gastroenterol Hepatol. 2025 Mar;23(4):680-681. 
  6. Chang KC, Su TH, Wu CK, Huang SC, Tseng TC, Hong CM, Hsu SJ, Liu CH, Yang HC, Liu CJ, Kao JH. Metabolic dysfunction-associated steatotic liver disease is associated with increased risks of heart failure. Eur J Heart Fail. 2025 Mar;27(3):512-520.
  7. Chang YC, Yen KC, Liang PC, Ho MC, Ho CM, Hsiao CY, Hsiao CH, Lu CH, Wu CH. Automated liver volumetry and hepatic steatosis quantification with magnetic resonance imaging proton density fat fraction. J Formos Med Assoc. 2025 Mar;124(3):264-270.
  8. Chang YP, Kao JH, Liu CH. Editorial: Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral-Induced Cure of Hepatitis C Virus Infection-Authors' Reply. Aliment Pharmacol Ther. 2025 May;61(9):1553-1554.
  9. Chang YP, Kao JH, Liu CH. Letter: Post-HCV Cure, Precision Assessment of Liver Stiffness and Diabetes Risk in Maternal Populations-A Critical Research Need. Authors' Reply. Aliment Pharmacol Ther. 2025 Jul;62(1):95-96.
  10. Chang YP, Kao JH, Liu CH. Response to "The unresolved link between MASLD and long-term ferritin dynamics in HCV-cured patients". J Formos Med Assoc. 2025 Dec 17:S0929-6646(25)00686-2. 
  11. Chang YP, Lee JY, Chen CY, Kao WY, Lin CL, Yang SS, Shih YL, Peng CY, Lee FJ, Tsai MC, Huang SC, Su TH, Tseng TC, Liu CJ, Chen PJ, Kao JH, Liu CH. Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral-Induced Cure of Hepatitis C Virus Infection. Aliment Pharmacol Ther. 2025 May;61(9):1508-1518.
  12. Chang KC, Su TH, Wu CK, Huang SC, Tseng TC, Hong CM, Hsu SJ, Liu CH, Yang HC, Liu CJ, Kao JH. Metabolic dysfunction-associated steatotic liver disease is associated with increased risks of heart failure. Eur J Heart Fail. 2025 Mar;27(3):512-520.
  13. Chen J, Ji D, Jia J, Zhuang H, Zhang X, Wang FS, Zhang W, Dou X, Tanwandee T, Sarin SK, Maiwall R, Kumar M, Goh GB, Ghazinyan H, Chutaputti A, Chen PJ, You H, Yu ML, George J, Omata M, Wang GQ, Lau G; APASL Viral Elimination Taskforce. Functional cure with new antiviral therapy for hepatitis B virus: a systematic review and meta-analysis. Hepatol Int. 2025 Aug;19(4):773-795
  14. Chen JY, Chang MH, Ho MC, Peng SF, Hsu WM, Lin WH, Wu JF. Hepatopulmonary syndrome in biliary atresia children increased postoperative complications after liver transplantation. Pediatr Neonatol. 2025 Jul;66(4):363-367.
  15. Chen KY, Lee PH, Ho CM. Recovery from severe herb-induced liver injury: a case report. Journal of the Formosan Medical Association 2025 Dec;124(12): 1195-7
  16. Chen WL, Chang YL, Lin SF, Protzer U, Isogawa M, Yang HC, Huang LR. Differential regulation of calcium-NFAT signaling pathway by Akt isoforms: unraveling effector dynamics and exhaustion of cytotoxic T lymphocytes in tumor microenvironment. J Immunother Cancer. 2025 Mar 26;13(3):e009827.
  17. Chen YC, Liu CJ, Su TH. Retina and liver fibrosis screening for patients with type 2 diabetes. Lancet Gastroenterol Hepatol. 2025 May;10(5):412-413.
  18. Chen YJ, Tai CS, Chang KC, Chen HL, Ni YH, Wu JF. Early predictors of intestinal complications in pediatric-onset Crohn's disease: A long-term cohort study in Taiwan. J Formos Med Assoc. 2025 Jul;124(7):644-649.
  19. Chien MM, Chang MH, Chang KC, Ni YH, Wu JF. The incidence of Clostridium difficile infection in children with and without inflammatory bowel diseases: A single-center study in Taiwan from 2006 to 2019. J Formos Med Assoc. 2025 Mar;124(3):253-257.
  20. Chung CY, Wang SH, Yeh SH, Chen PJ. Reply to: "Hepatitis B virus spliced 1 RNA, a key factor for viral expression". J Hepatol. 2025 Jan;82(1):e42-e43
  21. Chung JH, Tseng TC, Liu CH, Yang HC, Su TH, Chen PJ, Kao JH, Liu CJ. Evolution of qHBsAg levels in HBV/HCV co-infected patients with low serum HBV DNA: Comparison between treated versus untreated. J Formos Med Assoc. 2025 Apr 24:S0929-6646(25)00190-1. 
  22. D. Vasconcelos, M. H. Sodergren, V. Reebye, J. Vasara, M. S. Song, K. Holm,S. E. Khorsandi , J. Rossi, N. Habib , K. W. Huang*. Design and Evaluation of RNA Aptamer–Mediated Delivery of C/EBPβ siRNA for Oncological Therapy. Journal of Nucleic Acids. 2025 March 3;2025:1461574.
  23. Dongelmans EJ, Hirode G, Hansen BE, Chen CH, Su TH, Seto WK, Furquim d'Almeida A, van Hees S, Papatheodoridi M, Lens S, Wong GLH, Brakenhoff SM, Chien RN, Feld JJ, Chan HLY, Forns X, Papatheodoridis GV, Vanwolleghem T, Yuen MF, Hsu YC, Kao JH, Cornberg M, Sonneveld MJ, Jeng WJ, Janssen HLA; RETRACT-B study group. Predictors of hepatic flares after nucleos(t)ide analogue cessation - Results of a global cohort study (RETRACT-B study). J Hepatol. 2025 Mar;82(3):446-455. 
  24. Eslam M, Fan JG, Yu ML, Wong VW, Cua IH, Liu CJ, Tanwandee T, Gani R, Seto WK, Alam S, Young DY, Hamid S, Zheng MH, Kawaguchi T, Chan WK, Payawal D, Tan SS, Goh GB, Strasser SI, Viet HD, Kao JH, Kim W, Kim SU, Keating SE, Yilmaz Y, Kamani L, Wang CC, Fouad Y, Abbas Z, Treeprasertsuk S, Thanapirom K, Al Mahtab M, Lkhagvaa U, Baatarkhuu O, Choudhury AK, Stedman CAM, Chowdhury A, Dokmeci AK, Wang FS, Lin HC, Huang JF, Howell J, Jia J, Alboraie M, Roberts SK, Yoneda M, Ghazinian H, Mirijanyan A, Nan Y, Lesmana CRA, Adams LA, Shiha G, Kumar M, Örmeci N, Wei L, Lau G, Omata M, Sarin SK, George J. The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease. Hepatol Int. 2025 Apr;19(2):261-301.
  25. Fan SP, Chen YF, Li CH, Kuo YC, Lee NC, Chien YH, Hwu WL, Tseng TC, Su TH, Hsu CT, Chen HL, Lin CH, Ni YH. Plasma Glial Fibrillary Acidic Protein Correlates With Brain Metal Burden in Wilson's Disease Ann Clin Transl Neurol. 2025 Dec;12(12):2433-2445. 
  26. Ho CM, Hsu HH, Chen HL, Lee PH, Hu RH. Molecular evidence of solitary lung metastasis as the initial recurrence of hepatocellular carcinoma a decade more after liver transplantation. J Liver Transpl. 2025 May;18:100266
  27. Ho CM, Yeh CC, Wang JY, Hu RH, Lee PH. Preclass video nanolearning or microlearning in blended medical education. Frontiers in Medicine 2025 Oct;12:1639475
  28. Hong CM, Liu CJ. Response to comment on "Addition of neutrophil-to-lymphocyte ratio to Pre-DAA FIB-4 does not increase prediction value for de novo liver complications in hepatitis C". J Formos Med Assoc. 2025 Dec;124(12):1201.
  29. Hong CM, Su TH, Hsu SJ, Tseng TC, Liu CH, Yang HC, Kao JH, Chen PJ, Cheng PN, Hung CH, Peng CY, Chen CH, Lin CY, Kuo HT, Lin HC, Huang YH, Chen CY, Lin CL, Tsai PC, Zeng YS, Dai CY, Chuang WL, Huang JF, Huang CF, Yeh ML, Yu ML, Liu CJ. Addition of neutrophil-to-lymphocyte ratio to Pre-DAA FIB-4 does not increase prediction value for de novo liver complications in hepatitis C J Formos Med Assoc. 2025 Dec;124(12):1149-1156.
  30. Hsieh CL, Chang LY, Chen PJ, Yeh SH. HBV polymerase recruits the phosphatase PP1 to dephosphorylate HBc-Ser170 to complete encapsidation. PLoS Pathog. 2025 Feb 11;21(2):e1012905
  31. Hu PJ, Tsai PC, Chen CY, Kuo HT, Hung CH, Tseng KC, Lai HC, Peng CY, Wang JH, Chen JJ, Lee PL, Chien RN, Yang CC, Lo GH, Kao JH, Liu CJ, Liu CH, Yan SL, Lin CY, Su WW, Chu CH, Chen CJ, Tung SY, Tai CM, Lin CW, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Yeh ML, Huang CF, Hsieh MH, Huang JF, Dai CY, Chung WL, Wang YH, Yu ML, Bair MJ; T‐COACH Study Group. Impact of Hepatitis C Virus Clearance on Cardiovascular Risk: A Real-World Experience From the Nationwide Taiwan Hepatitis C Virus Registry. Kaohsiung J Med Sci. 2025 Aug;41(8):e70036.
  32. Hu PJ, Tsai PC, Chen CY, Kuo HT, Hung CH, Tseng KC, Lai HC, Peng CY, Wang JH, Chen JJ, Lee PL, Chien RN, Yang CC, Lo GH, Kao JH, Liu CJ, Liu CH, Yan SL, Lin CY, Su WW, Chu CH, Chen CJ, Tung SY, Tai CM, Lin CW, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Yeh ML, Huang CF, Hsieh MH, Huang JF, Dai CY, Chung WL, Wang YH, Yu ML, Bair MJ; T‐COACH Study Group. Impact of Hepatitis C Virus Clearance on Cardiovascular Risk: A Real-World Experience From the Nationwide Taiwan Hepatitis C Virus Registry. Kaohsiung J Med Sci. 2025 May 24:e70036 
  33. Hu PJ, Yu ML, Chen MY, Chen CY, Kuo HT, Hung CH, Tseng KC, Lai HC, Peng CY, Wang JH, Chen JJ, Lee PL, Chien RN, Yang CC, Lo GH, Kao JH, Liu CJ, Liu CH, Yan SL, Lin CY, Su WW, Chu CH, Chen CJ, Tung SY, Tai CM, Lin CW, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Yeh ML, Huang CF, Huang JF, Dai CY, Chung WL, Tsai PC, Bair MJ; T-COACH Study Group. Long-term risk of depression and the impact of risk factors among chronic hepatitis C patients after successful antiviral therapy: A nationwide real-world Taiwanese cohort (T-COACH). J Formos Med Assoc. 2025 Jun 9:S0929-6646(25)00269-4. 
  34. Huang MP, Hu RH, Cheng HY, Hsiao CY, Ho MC, Wu YM, Lee PH, Ho CM. Minor resection for primary hepatocellular carcinoma promotes curative recurrent treatments. Surgical Oncology 2025 Dec;63:102281
  35. Huang SC, Kao JH. Combining therapeutic agents to target the immune systems of hepatitis B patients: what do we need to consider? Expert Rev Gastroenterol Hepatol. 2025 Apr;19(4):371-375.
  36. Huang SC, Su TH, Tseng TC, Hsu SJ, Hong CM, Lan TY, Liu CH, Yang HC, Liu CJ, Kao JH. All-cause and cause-specific mortality in patients with chronic hepatitis B and concurrent steatotic liver disease J Hepatol. 2025 Jul;83(1):43-51.
  37. Huang SC, Su TH, Tseng TC, Hsu SJ, Hong CM, Lan TY, Liu CH, Yang HC, Liu CJ, Kao JH. All-cause and cause-specific mortality in patients with chronic hepatitis B and concurrent steatotic liver disease. J Hepatol. 2025 Jul;83(1):43-51. 
  38. Huang SC, Su TH, Tseng TC, Liao SH, Hsu SJ, Hong CM, Lan TY, Liu CH, Yang HC, Liu CJ, Kao JH. Pre-Existing and New-Onset Metabolic Dysfunctions Increase Cirrhosis and Its Complication Risks in Chronic Hepatitis B. Am J Gastroenterol. 2025 Feb 1;120(2):401-409.
  39. Huang SC, Su TH. Divergent roles of MASLD components in chronic hepatitis B: A double-edged sword J Hepatol. 2025 Jul;83(1):e34-e35.
  40. Huang SC, Kao JH. Combining therapeutic agents to target the immune systems of hepatitis B patients: what do we need to consider? Expert Rev Gastroenterol Hepatol. 2025 Apr;19(4):371-375.
  41. Huang SC, Kao JH. Viral Load-Based Prediction of Hepatocellular Carcinoma Risk in Noncirrhotic Patients With Chronic Hepatitis B. Ann Intern Med. 2025 Sep;178(9):1364.
  42. Huang SW, Lin CR, Chang YH, Ni YH, Chen HL, Liu HH. Cross-country multi-modal evidence links Aspergillus to biliary atresia. Gut Pathog. 2025 Nov 17;17(1):94
  43. Huang SC, Su TH, Tseng TC, Liao SH, Hsu SJ, Hong CM, Lan TY, Liu CH, Yang HC, Liu CJ, Kao JH. Pre-Existing and New-Onset Metabolic Dysfunctions Increase Cirrhosis and Its Complication Risks in Chronic Hepatitis B. Am J Gastroenterol. 2025 Feb 1;120(2):401-409. 
  44. Jang TY, Huang CF, Chang TS, Yang CC, Lo CC, Hung CH, Huang CW, Chong LW, Cheng PN, Yeh ML, Peng CY, Cheng CY, Huang JF, Bair MJ, Lin CL, Yang CC, Wang SJ, Hsieh TY, Lee TH, Lee PL, Wu WC, Lin CL, Su WW, Yang SS, Wang CC, Hu JT, Mo LR, Chen CT, Huang YH, Chang CC, Huang CS, Chen GY, Kao CN, Tai CM, Liu CJ, Lee MH, Tsai PC, Dai CY, Kao JH, Lin HC, Chuang WL, Tseng KC, Chen CY, Kuo HT, Yu ML. Impact of HCV eradication by directly acting antivirals on glycemic indices in chronic hepatitis C patients -a nationwide Taiwan HCV registry. J Formos Med Assoc. 2025 Aug;124(8):731-737.
  45. Lan TY, Lee TJ, Chang TW, Tseng TC, Lai PH, Cheng CF, Kao JH, Lin KY, Pai SY, Wu CH, Wang KY, Lo WY, Huang SC, Shen CY, Lu CH, Yang HC, Hsieh SC, Li KJ. Non-negligible risk of HBV reactivation among rheumatoid arthritis patients receiving JAK inhibitors: bridging the evidence gap. Rheumatology (Oxford). 2025 Dec 1;64(12):6168-6175. 
  46. Lee CJ, Hu YC, Chang HH, Chang KC, Tai CS, Ni YH, Chang MH, Wu JF. The relationship between lymphocyte subtypes distribution and biliary cirrhosis in biliary atresia patients. Pediatr Neonatol. 2025 Nov 13:S1875-9572(25)00204-9.
  47. Lee JW, Tai CS, Chang KC, Chiu YC, Ni YH, Wu JF. The benefits of transnasal endoscopy compared to conventional endoscopy in adolescents. J Formos Med Assoc. 2025 Dec;124(12):1167-1170.
  48. Lee SW, Yang SS, Tsai PC, Huang CF, Chen CY, Hung CH, Chen CH, Tai CM, Cheng PN, Kuo HT, Tseng KC, Mo LR, Lo CC, Huang YH, Lin HC, Lee PL, Bair MJ, Chang TS, Lin CY, Wang SJ, Hsieh TY, Yang TH, Peng CY, Yang CC, Chong LW, Huang CW, Lin CW, Chu CH, Tsai MC, Kao JH, Liu CJ, Chuang WL, Lee TY, Yu ML; TACR investigators. Direct-acting antiviral therapy for patients with hepatitis C virus-related hepatocellular carcinoma: A nationwide cohort study. Clin Mol Hepatol. 2025 Jul;31(3):899-913.
  49. Lee YC, Lee YH, Lu CW, Huang KC. Travel patterns, pretravel preparation, and travel-associated morbidity in travelers with diabetes in Taiwan. Travel Med Infect Dis. 2025 2025 Mar-Apr:64:102828.
  50. Li CL, Hsu CL, Lin YY, Ho MC, Hu RH, Tzeng ST, Wang YC, Tanaka Y, Chen PJ, Yeh SH. HBV DNA integration and somatic mutations in HCC patients with HBV-HCV dual infection reveals profiles intermediate between HBV- and HCV-related HCC. J Biomed Sci. 2025 Jan 2;32(1):2. 
  51. Liao CH, Tseng HH, Hong TC, Liu CJ. IgG4-associated autoimmune hepatitis in a 70-year-old woman with progressive liver failure: First case report in Taiwan. J Formos Med Assoc. 2025 Sep;124(9):865-866.
  52. Lin CJ, Chiang YC, Su TH, Shih IL, Kuo KT, Wei SC, Tai YJ. A Case of Uterine Adenosarcoma and Colonic Endometriosis Masquerading as Inflammatory Bowel Disease Dig Dis Sci. 2025 Jul;70(7):2229-2232. 
  53. Lin CL, Kao JH. Global strategies and actions to eliminate hepatitis B virus infection. Clin Mol Hepatol. 2025 Oct;31(4):1197-1212.
  54. Lin HY, Hsin KH, Liu CJ, Su TH, Yang WT, Huang SC, Hsu SJ, Yang HC, Liu CH, Chen PJ, Tseng TC, Kao JH. Hepatitis B core-related antigen kinetics predict spontaneous HBeAg seroclearance in chronic hepatitis B patients J Gastroenterol. 2025 Dec;60(12):1572-1583.
  55. Lin RB, Zhou L, Lin YC, Yu Y, Yang HC, Yu CW. A Machine Learning Framework for Cancer Prognostics: Integrating Temporal and Immune Gene Dynamics via ARIMA-CNN. Biomedicines. 2025 Nov 11;13(11):2751.
  56. Lin YC, Liao FM, Chao HC, Chen AC, Jeng YM, Lin CC, Tiao MM, Yang YJ, Yeung CY, Chen HL, Ni YH. Consensus Statement on Metabolic Dysfunction-Associated Steatotic Liver Disease in Children and Adolescents From the Joint TASL-TSPGHAN Expert Committee. JGH Open. 2025 Jun 12;9(6):e70137.
  57. Lin YC, Wu CC, Li YE, Chen CL, Lin CR, Ni YH. Full-length 16S rRNA sequencing reveals gut microbiome signatures predictive of MASLD in children with obesity. BMC Microbiol. 2025 Mar 17;25(1):146.
  58. Liu C, Liu CJ. Effects of Exercise Intervention in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease. J Obes Metab Syndr. 2025 Jul 30;34(3):239-252.
  59. Liu CH, Chang YP. Metabolic dysfunction in patients following DAA-induced viral cure for HCV infection: A non-negligible risk to liver-related health: Editorial on "Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C". Clin Mol Hepatol. 2025 Apr;31(2):658-661.
  60. Liu CH, Chang YP. Reply to correspondence on "Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C". Clin Mol Hepatol. 2025 Apr;31(2):e232-e233.
  61. Liu CH, Cheng PN, Fang YJ, Chen CY, Kao WY, Lin CL, Yang SS, Shih YL, Peng CY, Chang YP, Huang SC, Su TH, Tseng TC, Liu CJ, Chen PJ, Kao JH. Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infection. J Hepatol. 2025 Apr;82(4):582-593.
  62. Liu TH, Yang HC. Letter to the Editor: Clarifying the impact of response criteria and locoregional therapy on complete response outcomes in patients with hepatocellular carcinoma following immunotherapy. Hepatology. 2025 Nov 1;82(5):E136-E137.
  63. Liu WJ, Wu WJ, Lin CL, Liu CJ, Huang YW, Hu JT, Yu MW. Impact of age at HBsAg seroclearance on hepatic outcomes and life expectancy in men with chronic HBV infection based on multi-state modeling of the natural history. J Gastroenterol. 2025 Jan;60(1):107-117
  64. Liu CH, Cheng PN, Fang YJ, Chen CY, Kao WY, Lin CL, Yang SS, Shih YL, Peng CY, Chang YP, Huang SC, Su TH, Tseng TC, Liu CJ, Chen PJ, Kao JH. Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infection. J Hepatol. 2025 Apr;82(4):582-593.
  65. Lu CW, Chou TJ, Wu TY, Lee YH, Yang HJ, Huang KC. PNPLA3 and SAMM50 variants are associated with lean nonalcoholic fatty liver disease in Asian population. Ann. Hepatol. 2025 Jan-Jun;30(1):101761.
  66. Peng YC, Liao SH, Tsai JH, Chen PT, Chang CC, Kao JH, Liu KL. Comparison of the clinicoradiological features and outcomes of lymphoepithelioma-like cholangiocarcinoma and conventional intrahepatic cholangiocarcinoma: A propensity score matching analysis. J Formos Med Assoc. 2025 Aug;124(8):724-730. 
  67. Qin A, Ho MC, Tsai CY, Liu CJ, Chen PJ. Sequential combination with ropeginterferon alfa-2b and anti-PD-1 treatment as adjuvant therapy in HBV-related HCC: a phase 1 dose escalation trial. Hepatol Int. 2025 Jun;19(3):547-559
  68. Ruth Plummer, Mikael H. Sodergren, Rose Hodgson, Brı ́d M. Ryan, Nina Raulf, Joanna P. Nicholls, Vikash Reebye, Jon Voutila, Laura Sinigaglia, Tim Meyer, David J. Pinato, Debashis Sarker, Bristi Basu, Sarah Blagden,  Natalie Cook, Thomas R. Jeffrey Evans, Jeffrey Yachnin, Cheng E. Chee, Daneng Li, Anthony El-Khoueiry, Maria Diab, Kai-Wen Huang, Madhava Pai, Duncan Spalding, Thomas Talbot, Marcus S. Noel, Bridget Keenan, Devalingam Mahalingam, Min-Sun Song, Me ́ lanie Grosso, Denis Arnaud, Aurelie Auguste, Dimitris Zacharoulis, Jan Storkholm, Iain McNeish, Robert Habib, John J. Rossi. TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors. Cell Reports Medicine. 2025 April 15;6:102041.
  69. SC Huang, JH Kao. Viral Load-Based Prediction of Hepatocellular Carcinoma Risk in Noncirrhotic Patients With Chronic Hepatitis B. Ann Intern Med. 2025 Sep;178(9):1364.
  70. Shao YY, Chen CT, Chuang CH, Su TH, Ho MC, Tseng TC, Liu TH, Wu TC, Cheng AL, Hsu CH. Prompt initiation of durvalumab and tremelimumab for unresectable hepatocellular carcinoma in patients with chronic active hepatitis B: a phase 2 clinical trial. Br J Cancer. 2025 May;132(9):822-827. 
  71. Su TH, Kao JH. Old Dogs Play New Tricks: Alpha-Fetoprotein Dynamics in the Era of GALAD Score Gastroenterology. 2025 Jul;169(1):181-182. 
  72. Su TH, Kao JH. Response to Comment on "Fibrosis-4 index stratifies risks of hepatocellular carcinoma in patients with chronic hepatitis C″ J Formos Med Assoc. 2025 Nov;124(11):1098. 
  73. Su TH, Liao WC. Editorial: PIVKA-II Facilitates Risk Stratification for HCC Following HCV Cure. Aliment Pharmacol Ther. 2025 Feb;61(3):583-584. 
  74. Su TH, Yang SS, Lee MH, Kao WY, Huang SC, Chen FF, Poon FS, Tsai LW, Chen YT, Lin C, Wang W, Kim WR, Kao JH High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction-associated steatotic liver disease Clin Mol Hepatol. 2025 Jul;31(3):796-809.
  75. Tai CS, Chang KC, Chiu YC, Wu JF, Chen HL, Ni YH, Hsu HY, Chang MH. Clinical experience of infantile hepatic hemangioma. J Formos Med Assoc 2025; 124(5):446-451
  76. Tai JH, Lee DC, Lin HF, Chao TL, Ruan Y, Cheng YW, Chou YC, Lin YY, Chang SY, Chen PJ, Yeh SH, Wang HY. Tradeoffs between proliferation and transmission in virus evolution- insights from evolutionary and functional analyses of SARS-CoV-2. Virol J. 2025 Apr 19;22(1):107. 
  77. Tsai FP, Su TH, Huang SC, Tseng TC, Hsu SJ, Liao SH, Hong CM, Liu CH, Yang HC, Liu CJ, Chen PJ, Kao JH. Outcomes of radiofrequency ablation for hepatocellular carcinoma with concurrent steatotic liver disease. Cancer. 2025 Jan 1;131(1):e35541
  78. Tsai MM, Chang JC, Lu HY, Gau SS, Chien YH, Hwu WL, Ni YH, Chen HL, Lee NC. Long-term follow-up of neurocognitive function in patients with citrin deficiency and cholestasis. Clin Exp Pediatr. 2025; 68(3):257-265
  79. Tsai WT, Cheng A, Chuang YC, Ho CM, Wu YM, Ho MC, Sun HY, Hu RH, Chen YC. Cryptococcosis in wait-listed liver transplant candidates: Prevalence, manifestations, and risk factors. J Microbiol Immunol Infect. 2025 Feb;58(1):103-11
  80. Tseng TC, Hosaka T, Pan MH, Liu CJ, Suzuki F, Chen CJ, Su TH, Kumada H, Yang WT, Yang HC, Liu CH, Chen PJ, Yang HI, Kao JH. Higher level of HBsAg associated with delayed development of HCC in immune-tolerant patients. Hepatology. 2026 Jan 1;83(1):142-155.
  81. Tseng TC, Hsu YC, Su TH, Liu CH, Wang CC, Lin CL, Yang HI, Huang YH, Yang SS, Peng CY, Hu TH, Huang JF, Kao JH. Expert consensus on clinical usefulness of M2BPGi for managing chronic liver diseases. J Formos Med Assoc. 2025 Nov;124(11):1010-1017.
  82. Tseng TC, Huang SC, Pan MH, Liu CJ, Chen CJ, Yang WT, Tsai CH, Su TH, Yang HC, Liu CH, Chen PJ, Yang HI, Kao JH. Hepatitis B surface antigen level identifies patients with inactive chronic hepatitis B from Asia with HCC risk below surveillance threshold Gut. 2025 Oct 8;74(11):1896-1904. 
  83. Tung HN, Wu CH, Su TH. Letter to "Preoperative Prediction of Microvascular Invasion by EOB-MRI Imaging for Surgical Decision". Liver Cancer. 2024 Oct 17;14(3):351-352. 
  84. Wang SJ, Chang TS, Lo CC, Hung CH, Huang CW, Chong LW, Cheng PN, Bair MJ, Yeh ML, Peng CY, Cheng CY, Huang JF, Lin CL, Yang CC, Kuo HT, Hsieh TY, Lee TH, Lee PL, Wu WC, Lin CL, Su WW, Yang SS, Wang CC, Hu JT, Mo LR, Chen CT, Huang YH, Chang CC, Huang CS, Chen GY, Kao CN, Tai CM, Liu CJ, Lee MH, Tsai PC, Wang SC, Dai CY, Kao JH, Lin HC, Chuang WL, Tseng KC, Chen CY, Huang CF, Yu ML. Effects of Sofosbuvir/Velpatasvir Therapy on Extrahepatic Manifestations in Patients With Type 2 Diabetes and Chronic Hepatitis C: Insights From a Nationwide Hepatitis C Virus Registry in Taiwan. Kaohsiung J Med Sci. 2025 Jun 20:e70067 
  85. Wang SJ, Huang CF, Chang TS, Lo CC, Hung CH, Huang CW, Chong LW, Cheng PN, Yeh ML, Peng CY, Cheng CY, Huang JF, Bair MJ, Lin CL, Yang CC, Kuo HT, Hsieh TY, Lee TH, Lee PL, Wu WC, Lin CL, Su WW, Yang SS, Wang CC, Hu JT, Mo LR, Chen CT, Huang YH, Chang CC, Huang CS, Chen GY, Kao CN, Tai CM, Liu CJ, Lee MH, Tsai PC, Dai CY, Kao JH, Lin HC, Chuang WL, Tseng KC, Chen CY, Wang SC, Yu ML. Real-world efficacy and safety of universal 8-week glecaprevir/pibrentasvir in patients with chronic hepatitis C with early chronic kidney disease or pre-end-stage renal disease: Insights from a nationwide hepatisis C virus registry in Taiwan. Kaohsiung J Med Sci. 2025 Feb;41(2):e12929
  86. Wang SW, Wang C, Cheng YM, Chen CY, Hsieh TH, Wang CC, Kao JH. Genetic predisposition of metabolic dysfunction-associated steatotic liver disease: a population-based genome-wide association study. Hepatol Int. 2025 Apr;19(2):415-427
  87. Wang SW, Wang C, Cheng YM, Hsieh TH, Wang CC, Kao JH. Liver and atherosclerotic risk of alcohol consumption in patients with metabolic dysfunction-associated Steatotic Liver Disease. Atherosclerosis. 2025 Apr;403:119161.
  88. Wang YC, Wu PH, Ting WC, Wang YF, Yang MH, Su TH, Su JY, Sun HI, Huang WM, Tsai PL, Wernig G, Ho PC, Wang L, Wu CT, Chang YL, Chen TC, Meng TC, Chang YM, Lai SL, Li CW, Ko TM, Yang KC, Chang YJ, Chern Y, Kuo MC, Huang YT, Tzeng YS, Tang JL, Chen SY. Single-cell signaling network profiling during redox stress reveals dynamic redox regulation in immune cells Nat Commun. 2025 Jul 1;16(1):5600.
  89. Wu CH, Yen KC, Wang LY, Hsieh PL, Wu WK, Lee PL, Liu CJ. Automated Whole-Liver Fat Quantification with Magnetic Resonance Imaging-Derived Proton Density Fat Fraction Map: A Prospective Study in Taiwan. Gut Liver. 2025 Jul 15;19(4):617-626
  90. Wu D, Kao JH, Piratvisuth T, Wang X, Kennedy PTF, Otsuka M, Ahn SH, Tanaka Y, Wang G, Yuan Z, Li W, Lim YS, Niu J, Lu F, Zhang W, Gao Z, Kaewdech A, Han M, Yan W, Ren H, Hu P, Shu S, Kwo PY, Wang FS, Yuen MF, Ning Q. Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0. Clin Mol Hepatol. 2025 Feb;31(Suppl):S134-S164.
  91. Wu JF, Tai CS, Chang KC, Chen YJ, Hsu CT, Chen HL, Ni YH, Chang MH. Predictors of functional cure of chronic hepatitis B virus infection - A long-term follow-up study. Clin Gastroenterol Hepatol. 2025; 23(4):583-590
  92. Wu WJ, Liu WJ, Lin CL, Liu CJ, Huang YW, Hu JT, Yu MW. Impact of tenofovir vs. entecavir treatment on progression of chronic hepatitis B: A nationwide cohort study. JHEP Rep. 2025 Jul 5;7(10):101511.
  93. Yu LC, Wei SC, Li YH, Huang CY, Pai YC, Hung YM, Lai LC, Ni YH. Phenotypic characterization and complete genome of a tumorigenic pathobiont Escherichia coli LI60C3. Gut Pathog. 2025 Aug 20;17(1):63.
     

新聞亮點

新聞報紙